Skip to content

A multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group comparison trial to investigate the effect of nalmefene on alcohol consumption reduction in patients with alcohol dependence (phase 3 trial)

A multicenter, randomized, double-blind, placebo-controlled, 3-parallel-group comparison trial to investigate the effect of nalmefene on alcohol consumption reduction in patients with alcohol dependence (phase 3 trial)

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCT2080222752
Enrollment
660
Registered
2015-02-12
Start date
2015-02-09
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alcohol dependent

Interventions

Sponsors

Otsuka Pharmaceutical Co., Ltd.
Lead Sponsor
H. Lundbeck A/S
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: - Japanese males and females aged 20 or above who have signed the informed consent form. - The patient has alcohol dependence, diagnosed according to Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-4-TR) and confirmed by Mini-international Neuropsychiatric Interview (M.I.N.I.).

Exclusion criteria

Exclusion criteria: - The patient with a current diagnosis or history of substance use disorders (except for alcohol, nicotine, and caffeine), according to DSM-4-TR and confirmed by M.I.N.I.. - The patient has reported current use of, or has tested positive for, drugs of abuse (opiates, methadone, cocaine, amphetamines, barbiturates) at the screening test.

Design outcomes

Primary

MeasureTime frame
efficacy The number of Heavy Drinking Days (HDDs) Change in the number of HDDs from baseline at Week 12 of the treatment period

Secondary

MeasureTime frame
efficacy Total alcohol consumption (TAC) Change in TAC from baseline at Week 12 of the treatment period

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026